These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 32297438)

  • 41. Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study.
    Zou Z; Xing P; Hao X; Wang Y; Song X; Shan L; Zhang C; Liu Z; Ma K; Dong G; Li J
    BMC Med; 2022 Jan; 20(1):12. PubMed ID: 35039026
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characteristics of central nervous system progression in non-small cell lung cancer treated with crizotinib or alectinib.
    Sakamoto H; Yanagitani N; Manabe R; Tsugitomi R; Ogusu S; Tozuka T; Yoshida H; Amino Y; Ariyasu R; Uchibori K; Kitazono S; Tasaka S; Nishio M
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1414. PubMed ID: 33960745
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
    Tamura T; Kiura K; Seto T; Nakagawa K; Maemondo M; Inoue A; Hida T; Yoshioka H; Harada M; Ohe Y; Nogami N; Murakami H; Kuriki H; Shimada T; Tanaka T; Takeuchi K; Nishio M
    J Clin Oncol; 2017 May; 35(14):1515-1521. PubMed ID: 28296581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
    Pérol M; Pavlakis N; Levchenko E; Platania M; Oliveira J; Novello S; Chiari R; Moran T; Mitry E; Nüesch E; Liu T; Balas B; Konopa K; Peters S
    Lung Cancer; 2019 Dec; 138():79-87. PubMed ID: 31654838
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study.
    Lin JJ; Muzikansky A; Kennedy E; Kuberski H; Stober LL; Wanat AC; Azzoli CG; Lennes I; Sequist LV; Dagogo-Jack I; Shaw AT; Gainor JF
    ESMO Open; 2022 Feb; 7(1):100342. PubMed ID: 34896762
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: Real-World Data.
    Jeon Y; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
    Cancer Res Treat; 2024 Jan; 56(1):61-69. PubMed ID: 37448121
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
    Burudpakdee C; Wong W; Seetasith A; Corvino FA; Yeh W; Gubens M
    Lung Cancer; 2018 May; 119():103-111. PubMed ID: 29656744
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.
    Hotta K; Hida T; Nokihara H; Morise M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Yoshimoto T; Takata S; Tamura T
    ESMO Open; 2022 Aug; 7(4):100527. PubMed ID: 35843080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort.
    Dziadziuszko R; Mok T; Peters S; Han JY; Alatorre-Alexander J; Leighl N; Sriuranpong V; Pérol M; de Castro Junior G; Nadal E; de Marinis F; Frontera OA; Tan DSW; Lee DH; Kim HR; Yan M; Riehl T; Schleifman E; Paul SM; Mocci S; Patel R; Assaf ZJ; Shames DS; Mathisen MS; Gadgeel SM
    J Thorac Oncol; 2021 Dec; 16(12):2040-2050. PubMed ID: 34311110
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.
    Crvenkova S
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Sep; 41(2):29-36. PubMed ID: 33011694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study).
    Hizal M; Bilgin B; Paksoy N; Atcı MM; Kahraman S; Kılıçkap S; Güven DC; Keskinkılıç M; Ayhan M; Eren Ö; Mustafayev FNA; Yaman Ş; Bayram E; Ertürk İ; Özcan E; Korkmaz M; Akagündüz B; Erdem D; Telli TA; Aksoy A; Üskent N; Baytemür NK; Gülmez A; Aydın D; Şakalar T; Arak H; Tatlı AM; Ergün Y; Ak N; Ünal Ç; Özgün MA; Yalçın B; Öztop İ; Algın E; Sakin A; Aydıner A; Yumuk PF; Şendur MAN
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4141-4148. PubMed ID: 36048274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
    Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Efficacy of Alectinib in Patients with
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.
    Yoshida T; Oya Y; Tanaka K; Shimizu J; Horio Y; Kuroda H; Sakao Y; Hida T; Yatabe Y
    Lung Cancer; 2016 Jul; 97():43-7. PubMed ID: 27237026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
    Nishio M; Yoshida T; Kumagai T; Hida T; Toyozawa R; Shimokawaji T; Goto K; Nakagawa K; Ohe Y; Seto T; Kudou K; Asato T; Zhang P; Yamamoto N
    J Thorac Oncol; 2021 Mar; 16(3):452-463. PubMed ID: 33248320
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
    Gadgeel S; Shaw AT; Barlesi F; Crinò L; Yang JC; Dingemans AC; Kim DW; de Marinis F; Schulz M; Liu S; Gupta R; Kotb A; Ou SI
    Br J Cancer; 2018 Jan; 118(1):38-42. PubMed ID: 29149104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
    Ou SI; Gadgeel SM; Barlesi F; Yang JC; De Petris L; Kim DW; Govindan R; Dingemans AM; Crino L; Léna H; Popat S; Ahn JS; Dansin E; Mitry E; Müller B; Bordogna W; Balas B; Morcos PN; Shaw AT
    Lung Cancer; 2020 Jan; 139():22-27. PubMed ID: 31706099
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical features of the ALK-mutant non-small cell lung cancer patients who received first-line alectinib treatment].
    Hızal M; Bilgin B; Şendur MA; Yücel Ş; Kahraman S; Erol C; Akıncı B; Şener Dede D; Algın E; Yalçın B
    Tuberk Toraks; 2021 Sep; 69(3):321-327. PubMed ID: 34581153
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.
    Metro G; Lunardi G; Bennati C; Chiarini P; Sperduti I; Ricciuti B; Marcomigni L; Costa C; Crinò L; Floridi P; Gori S; Chiari R
    J Neurooncol; 2016 Sep; 129(2):355-61. PubMed ID: 27324494
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.